Shares of Regulus Therapeutics Inc (NASDAQ:RGLS) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $1.75 and last traded at $1.77, with a volume of 1519 shares. The stock had previously closed at $1.88.
A number of brokerages have recently issued reports on RGLS. Wedbush reiterated a “hold” rating and set a $2.00 target price on shares of Regulus Therapeutics in a report on Tuesday, October 9th. Zacks Investment Research upgraded Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a report on Saturday, October 13th. Wells Fargo & Co decreased their price target on Regulus Therapeutics from $1.50 to $1.00 and set a “market perform” rating for the company in a report on Friday, July 6th. ValuEngine cut Regulus Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, July 2nd. Finally, B. Riley decreased their price target on Regulus Therapeutics from $1.00 to $0.50 and set a “neutral” rating for the company in a report on Friday, July 6th. Eight analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $1.42.
The firm has a market capitalization of $16.41 million, a price-to-earnings ratio of -0.15 and a beta of 1.38.
A hedge fund recently bought a new stake in Regulus Therapeutics stock. A.R.T. Advisors LLC acquired a new position in shares of Regulus Therapeutics Inc (NASDAQ:RGLS) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 169,416 shares of the biopharmaceutical company’s stock, valued at approximately $121,000. A.R.T. Advisors LLC owned approximately 0.16% of Regulus Therapeutics as of its most recent SEC filing.
About Regulus Therapeutics (NASDAQ:RGLS)
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Recommended Story: How Important is Technical Analysis of Stocks
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.